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Cardiorenal Syndrome
Claudio Ronco, MD,* Mikko Haapio, MD,† Andrew A. House, MSC, MD,‡ Nagesh Anavekar, MD,§
Rinaldo Bellomo, MD¶
Vicenza, Italy; Helsinki, Finland; London, Ontario, Canada; and Melbourne, Australia
The term cardiorenal syndrome (CRS) increasingly has been used without a consistent or well-accepted defini-
tion. To include the vast array of interrelated derangements, and to stress the bidirectional nature of heart-
kidney interactions, we present a new classification of the CRS with 5 subtypes that reflect the pathophysiology,
the time-frame, and the nature of concomitant cardiac and renal dysfunction. CRS can be generally defined as a
pathophysiologic disorder of the heart and kidneys whereby acute or chronic dysfunction of 1 organ may induce
acute or chronic dysfunction of the other. Type 1 CRS reflects an abrupt worsening of cardiac function (e.g.,
acute cardiogenic shock or decompensated congestive heart failure) leading to acute kidney injury. Type 2 CRS
comprises chronic abnormalities in cardiac function (e.g., chronic congestive heart failure) causing progressive
chronic kidney disease. Type 3 CRS consists of an abrupt worsening of renal function (e.g., acute kidney isch-
emia or glomerulonephritis) causing acute cardiac dysfunction (e.g., heart failure, arrhythmia, ischemia). Type 4
CRS describes a state of chronic kidney disease (e.g., chronic glomerular disease) contributing to decreased car-
diac function, cardiac hypertrophy, and/or increased risk of adverse cardiovascular events. Type 5 CRS reflects a
systemic condition (e.g., sepsis) causing both cardiac and renal dysfunction. Biomarkers can contribute to an
early diagnosis of CRS and to a timely therapeutic intervention. The use of this classification can help physicians
characterize groups of patients, provides the rationale for specific management strategies, and allows the de-
sign of future clinical trials with more accurate selection and stratification of the population under
investigation. (J Am Coll Cardiol 2008;52:1527–39) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.07.051C
T
k
a
k
r
C
a
c
a
l
c
m
t
f
t
b
n
r
t
C
a
k
blarge proportion of patients admitted to hospital have
arious degrees of heart and kidney dysfunction (1). Primary
isorders of 1 of these 2 organs often result in secondary
ysfunction or injury to the other (2). Such interactions
epresent the pathophysiological basis for a clinical entity
alled cardiorenal syndrome (CRS) (3). Although generally
efined as a condition characterized by the initiation and/or
rogression of renal insufficiency secondary to heart failure
4), the term CRS is also used to describe the negative
ffects of reduced renal function on the heart and circulation
5). The absence of a clear definition and the complexity of
his cluster of conditions contribute to lack of clarity with
egard to diagnosis and management (6). This is unfortu-
ate, because recent advances in basic and clinical sciences
ave improved our understanding of organ crosstalk and
ave demonstrated the efficacy of some therapies in atten-
ating both cardiac and renal injury (7). Thus, a more
rticulated definition in terms of clinical presentation, patho-
hysiology, diagnosis, and management is needed to explore
he complex nature of CRS and its different clinical subtypes.
rom the *Department of Nephrology, St. Bortolo Hospital, Vicenza, Italy; †Division
f Nephrology, Helsinki University Central Hospital, Helsinki, Finland; ‡Division of
ephrology, London Health Sciences Centre, London, Ontario, Canada; §Depart-
ent of Cardiology, Northern Hospital, Melbourne, Australia; and the ¶Department
f Intensive Care, Austin Hospital, Melbourne, Australia.w
Manuscript received June 12, 2008; revised manuscript received July 14, 2008,
ccepted July 28, 2008.RS: A Definition
he simplistic view of CRS is that a relatively normal
idney is dysfunctional because of a diseased heart, with the
ssumption that, in the presence of a healthy heart, the same
idney would perform normally (8). This concept has been
ecently challenged, and a more articulated definition of the
RS has been advocated (5). The CRS includes a variety of
cute or chronic conditions, where the primary failing organ
an be either the heart or the kidney (9).
Previous terminology did not allow physicians to identify
nd fully characterize the chronology of the pathophysio-
ogical interactions that characterize a specific type of
ombined heart/kidney disorder. A diseased heart has nu-
erous negative effects on kidney function but, at the same
ime, renal insufficiency can significantly impair cardiac
unction (9). Thus, direct and indirect effects of each organ
hat is dysfunctional can initiate and perpetuate the com-
ined disorder of the 2 organs through a complex combi-
ation of neurohormonal feedback mechanisms. For this
eason, a subdivision of CRS into 5 different subtypes seems
o provide a more concise and logically correct approach.
RS type 1 (acute CRS). Type 1 CRS is characterized by
rapid worsening of cardiac function, leading to acute
idney injury (AKI) (Fig. 1). Acute heart failure (HF) may
e divided into 4 subtypes: hypertensive pulmonary edema
ith preserved left ventricular (LV) systolic function,
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Cardiorenal Syndrome November 4, 2008:1527–39acutely decompensated chronic
HF, cardiogenic shock, and pre-
dominant right ventricular fail-
ure (10). Type 1 CRS is a com-
mon occurrence. More than 1
million patients in the U.S. are
admitted to the hospital every
year with either de novo acute
HF or acutely decompensated
chronic HF (11). Among these
patients, pre-morbid chronic re-
nal dysfunction is a common oc-
currence and predisposes them to
AKI (12,13). The mechanisms
by which the onset of acute HF
or acutely decompensated chronic
HF leads to AKI are multiple
and complex (4) (Fig. 1). The
clinical importance of each
mechanism is likely to vary from
patient to patient (e.g., acute car-
diogenic shock vs. hypertensive
pulmonary edema) and situation
to situation (acute HF secondary
to perforation of a mitral valve
leaflet from endocarditis vs.
orsening right HF secondary to noncompliance with
iuretic therapy). In acute HF, AKI appears to be more
evere in patients with impaired LV ejection fraction com-
ared with those with preserved LV function, achieving an
ncidence 70% in patients with cardiogenic shock (14).
urthermore, impaired renal function is consistently found
s an independent risk factor for 1-year mortality in acute
F patients, including patients with ST-segment elevation
yocardial infarction (15). A plausible reason for this
ndependent effect might be that an acute decline in renal
unction does not simply act as a marker of illness sever-
ty but also carries an associated acceleration in cardiovas-
ular pathobiology through activation of inflammatory
athways (9,16).
In CRS type 1, a salient clinical issue is how the onset of
KI impacts on prognosis and treatment of acute HF. The
rst clinical principle is that the onset of AKI in this setting
mplies inadequate renal perfusion until proven otherwise,
hich should prompt clinicians to consider the diagnosis of
low cardiac output state and/or marked increase in venous
ressure leading to kidney congestion through the use of
hysical examination, ancillary signs, imaging, and labora-
ory findings.
The second important consequence of type 1 CRS is
ecreased diuretic responsiveness. In a congestive state,
ecreased response to diuretics may result from the physi-
logical phenomena of diuretic braking (diminished diuretic
ffectiveness secondary to postdiuretic sodium retention)
17) and post-diuretic sodium retention (18). In addition,
Abbreviations
and Acronyms
ACE  angiotensin-
converting enzyme
AKI  acute kidney injury
ARB  angiotensin
receptor blocker
BNP  B-type natriuretic
peptide
CKD  chronic kidney
disease
CRS  cardiorenal
syndrome
GFR  glomerular filtration
rate
HF  heart failure
ICU  intensive care unit
IL  interleukin
LV  left ventricular
NGAL  neutrophil
gelatinase-associated
lipocalin
TNF  tumor necrosis
factoroncerns of aggravating AKI by the administration of aiuretics at greater doses or in combination also can act as an
dditional, iatrogenic mechanism. Diuretics are best pro-
ided to HF patients with evidence of systemic fluid
verload with the goal of achieving a gradual diuresis. Loop
iuretics may be titrated according to renal function, systolic
lood pressure, and history of chronic diuretic use. High
oses may cause tinnitus, and a continuous low-dose di-
retic infusion might be more efficient (19).
Measurement of cardiac output (arterial pressure monitoring
ombined with pulse contour analysis or by Doppler ultra-
ound) and venous pressure may help ensure adequate and
argeted diuretic therapy (20–22) and allow safer navigation
hrough the precarious situation of combined HF and AKI.
f diuretic-resistant fluid overload exists despite an opti-
ized cardiac output, removal of isotonic fluid can be
chieved by the use of extracorporeal ultrafiltration (23,24).
The presence of AKI with or without concomitant
yperkalemia may also affect patient outcome by inhibiting
he prescription of angiotensin-converting enzyme (ACE)
nhibitors, angiotensin receptor blockers (ARBs), and aldo-
terone inhibitors (drugs that have been shown in large
andomized controlled trials to increase survival in the
etting of heart failure and myocardial infarction) (25).
owever, provided there is close monitoring of renal function
nd potassium levels, the potential benefits of these interven-
ions often outweigh their risks, even in these patients.
The acute administration of beta-blockers in the setting
f type 1 CRS generally is not advised. Such therapy should
ait until the patient has stabilized physiologically and until
oncerns about a low output syndrome have been resolved.
n some patients, stroke volume cannot be increased, and
elative or absolute tachycardia sustains the adequacy of
ardiac output. Blockade of such compensatory tachycardia
nd sympathetic system-dependent inotropic compensation
an precipitate cardiogenic shock with associated high
ortality (26). Particular concern applies to beta-blockers
xcreted by the kidney, such as atenolol or sotalol, alone or
n combination with calcium antagonists (27). This should
ot inhibit the slow, careful, titrated administration of beta-
lockers later on, once patients are hemodynamically stable.
In patients with kidney dysfunction, undertreatment after
yocardial infarction is common (28). Attention should be
aid to preserving renal function, perhaps with the same
igor as we attempt to salvage and protect cardiac muscle.
orsening of renal function during admission for ST-
egment elevation myocardial infarction is a powerful and
ndependent predictor of in-hospital and 1-year mortality
14,15). In patients who receive percutaneous coronary
ntervention or cardiac surgery, even a small increase in
erum creatinine (0.3 mg/dl) is associated with increased
ospital stay and mortality (29,30). In this context, an
ncrease in creatinine is not simply a marker of illness
everity but, rather, it represents the onset of AKI acting as
causative factor for cardiovascular injury acceleration
hrough the activation of neurohormonal, immunological
nd inflammatory pathways (9,16). No specific kidney-
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November 4, 2008:1527–39 Cardiorenal Syndromerotective treatments have yet emerged for this condition.
espite some initial promising results, the use of nesiritide
emains controversial, and a recent negative randomized
ontrolled trial in these very patients (31) suggests that this
gent is unlikely to have significant clinical benefit.
A very specific and common threat to kidney function in
he setting of acute cardiac disease relates to the adminis-
ration of radiocontrast for heart imaging procedures. This
opic, recently reviewed in the Journal (32), would require
eparate detailed discussion and is beyond the scope of this
rticle. Suffice it to say that this high-risk group requires
ppropriate prophylaxis to avoid radiocontrast nephropathy.
iven that the presence of type 1 CRS defines a population
ith high mortality, a prompt, careful, systematic, multi-
isciplinary approach involving cardiologists, nephrologists,
ritical care physicians, and cardiac surgeons is both logical
nd desirable.
In CRS type 1, the early diagnosis of AKI remains a
hallenge (33). This is also true in CRS type 3, where AKI
Figure 1 CRS Type 1
Pathophysiological interactions between heart and kidney in type 1 cardiorenal syn
genic shock or acute decompensation of chronic heart failure) leading to kidney in
B-type natriuretic peptide; CO  cardiac output; GFR  glomerular filtration rate; K
 renin angiotensin aldosterone. Figure illustration by Rob Flewell.s believed to be the primary inciting factor leading to cardiac dysfunction. In both cases, classic markers such as
reatinine increase when AKI is already established and very
ittle can be done to prevent it or to protect the kidney. An
nteresting evolution in the early diagnosis of CRS has been
he discovery of novel AKI biomarkers. With the use of a
omplementary deoxyribonucleic acid microarray as a
creening technique, a subset of genes whose expression is
p-regulated within the first few hours after renal injury has
een discovered (34,35).
Neutrophil gelatinase-associated lipocalin (NGAL) ap-
ears to be one of the earliest markers detected in the blood
nd urine of humans with AKI (36–39). Urine and serum
GAL are early predictors of AKI both in adult and
hildren either in cardiac surgery or patients in the intensive
are unit (ICU) (40,41). In these patients, an increase in
reatinine is observed only 48 to 72 h later (42). NGAL
s also a biomarker of delayed graft function in kidney
ransplantation (43), AKI caused by contrast-media (44),
nd AKI in critically ill patients admitted to intensive
(CRS) or “acute CRS” (abrupt worsening of cardiac function, e.g., acute cardio-
CE  angiotensin-converting enzyme; ANP  atrial natriuretic peptide; BNP 
kidney injury molecule; N-GAL  neutrophil gelatinase-associated lipocalin; RAAdrome
jury. A
IM are (45).
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Cardiorenal Syndrome November 4, 2008:1527–39Cystatin C appears to be a better predictor of glomerular
unction than serum creatinine in patients with chronic
idney disease (CKD) because its blood levels are not
ffected by age, gender, race, or muscle mass (46). Cystatin
predicts AKI and the requirement for renal replacement
herapy earlier than creatinine (47). Serum cystatin C has
een compared with NGAL in cardiac surgery-mediated
KI (48). Both biomarkers predicted AKI at 12 h, although
GAL outperformed cystatin C at earlier time points.
onsidering them together, they may represent a combina-
ion of structural and functional damage of the kidney.
Kidney injury molecule 1 is a protein detectable in the
rine after ischemic or nephrotoxic insults to proximal
ubular cells (49–51) and seems to be highly specific for
schemic AKI. Combined with NGAL which is highly
ensitive, it may represent an important marker in the early
hases of AKI.
Biomarkers such as N-acetyl--(D)glucosaminidase (52),
nterleukin (IL)-18 (53) and others reported in Table 1 have
een proposed as an interesting and promising contribution
o diagnosis of AKI and progression of CKD. The most
ikely evolution will be a “panel” of biomarkers that include
everal molecules both in serum and urine that combine
heir best characteristics in terms of specificity and sensitiv-
ty of each marker molecule.
RS type 2 (chronic CRS). Type 2 CRS is characterized
y chronic abnormalities in cardiac function (e.g., chronic
ongestive HF) causing progressive CKD (Fig. 2). Wors-
ning renal function in the context of HF is associated with
dverse outcomes and prolonged hospitalizations (32). The
revalence of renal dysfunction in chronic HF has been
eported to be approximately 25% (54). Even slight de-
reases in estimated glomerular filtration rate (GFR) signif-
cantly increase mortality risk (54) and are considered a
arker of severity of vascular disease (55). Independent
redictors of worsening function include old age, hyperten-
ion, diabetes mellitus, and acute coronary syndromes.
The mechanisms underlying worsening renal function
ikely differs based on acute versus chronic HF. Chronic HF
rotein Biomarkers forhe Early Detection of Acute Kidney Injury
Table 1 Protein Biomarkers forthe Early Detection of Acute Kidney Injury
Biomarker Associated Injury
Cystatin C Proximal tubule injury
KIM-1 Ischemia and nephrotoxins
NGAL (lipocalin) Ischemia and nephrotoxins
NHE3 Ischemia, pre-renal, post-renal AKI
Cytokines (IL-6, IL-8, IL-18) Toxic, delayed graft function
Actin-actin depolymerizing F Ischemia and delayed graft function
-GST Proximal T injury, acute rejection
-GST Distal tubule injury, acute rejection
L-FABP Ischemia and nephrotoxins
Netrin-1 Ischemia and nephrotoxins, sepsis
Keratin-derived chemokine Ischemia and delayed graft function
ST  glutathione S-transferase; IL  interleukin; KIM  kidney injury molecule; L-FABP  L-typeH
atty acid binding protein; NGAL  neutrophil gelatinase-associated lipocalin; NHE  sodium-
ydrogen exchanger.s likely to be characterized by a long-term situation of
educed renal perfusion, often predisposed by microvascular
nd macrovascular disease. Although a greater proportion of
atients with low estimated GFR have a worse New York
eart Association functional class, no evidence of associa-
ion between LV ejection fraction and estimated GFR can
e consistently demonstrated. Thus, patients with chronic
F and preserved LV function appear to have similar
stimated GFR than patients with impaired LV (ejection
raction 45%) (55).
There is very limited understanding of the pathophys-
ology of renal dysfunction in the setting of even ad-
anced cardiac failure. In this setting, where one would
ntuitively consider hemodynamic issues to be dominant,
he ESCAPE (Evaluation Study of Congestive Heart Fail-
re and Pulmonary Catheterization Effectiveness) trial (56)
ound no link between any pulmonary artery catheter-
easured hemodynamic variables and serum creatinine in
94 patients. The only link was with right atrial pressure,
uggesting that renal congestion may be more important
han appreciated. Clearly, hypoperfusion alone cannot ex-
lain renal dysfunction in this setting. More work needs to
e performed to understand the mechanisms at play to develop
argeted and physiologically sound approaches to treatment.
Neurohormonal abnormalities are present with excessive
roduction of vasoconstrictive mediators (epinephrine, an-
iotensin, endothelin) and altered sensitivity and/or release
f endogenous vasodilatory factors (natriuretic peptides,
itric oxide). Pharmacotherapies used in the management
f HF may worsen renal function. Diuresis-associated
ypovolemia, early introduction of renin-angiotensin-
ldosterone system blockade, and drug-induced hypoten-
ion have all been suggested as contributing factors (4).
More recently, there has been increasing interest in the
athogenic role of relative or absolute erythropoietin defi-
iency contributing to a more pronounced anemia in these
atients than might be expected for renal failure alone (57).
rythropoietin receptor activation in the heart may protect
t from apoptosis, fibrosis, and inflammation (58,59). Pre-
iminary clinical studies show that erythropoiesis-
timulating agents in patients with chronic HF, CKD, and
nemia lead to improved cardiac function, reduction in LV
ize, and the lowering of B-type natriuretic peptide (BNP)
60). Patients with type 2 CRS are more likely to receive
oop diuretics and vasodilators and also to receive greater
oses of such drugs compared with those patients with
table renal function (61). Treatment with these drugs may
articipate in the development and progression of renal
njury. However, such therapies may simply identify patients
ith severe hemodynamic compromise and, thus, a predis-
osition to renal dysfunction rather than being responsible
or worsening function.
Renal insufficiency is highly prevalent among patients
ith HF and is an independent negative prognostic factor in
oth diastolic and systolic ventricular dysfunction and severe
F (62). The logical practical implications of the plethora
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November 4, 2008:1527–39 Cardiorenal Syndromef data linking CKD with cardiovascular disease are that
ore attention needs to be paid to reducing risk factors and
ptimizing medications in these patients and that under-
reatment due to concerns about pharmacodynamics in this
etting may have lethal consequences at an individual level
nd huge potential adverse consequences at a public health
evel. Nonetheless, it is equally important to acknowledge
hat clinicians looking after these patients often are faced
ith competing therapeutic choices and that, with the
xception of MERIT-HF (Metoprolol Controlled-Release
andomised Intervention Trial in Heart Failure) (63), large
andomized controlled trials that have shaped the treatment
f chronic HF in the last 2 decades have consistently
xcluded patients with significant renal disease. More on the
se of specific agents is covered in the sections on type 3 and
CRS.
RS type 3 (acute renocardiac syndrome). Type 3 CRS is
haracterized by an abrupt and primary worsening of kidney
unction (e.g., AKI, ischemia, or glomerulonephritis), lead-
Figure 2 CRS Type 2
Pathophysiological interactions between heart and kidney in type 2 cardiorenal syn
e.g., chronic heart failure) causing progressive chronic kidney disease (CKD). Figur
sin aldosterone.ng to acute cardiac dysfunction (e.g., HF, arrhythmia, cschemia). Type 3 CRS appears less common than type 1
RS, but this may only be due to the fact that, unlike type
CRS, it has not been systematically studied. AKI is a
rowing disorder in hospital and ICU patients. When the
IFLE (risk, injury, and failure; loss; and end-stage kidney
isease) consensus definition is used, AKI has been identi-
ed in close to 9% of hospital patients (64). In a large ICU
atabase, AKI was observed in more than 35% of patients
65). Acute kidney injury can affect the heart through
everal pathways (Fig. 3), whose hierarchy is not yet
stablished. Fluid overload can contribute to the develop-
ent of pulmonary edema. Hyperkalemia can contribute to
rrhythmias and may cause cardiac arrest. Untreated uremia
ffects myocardial contractility through the accumulation of
yocardial depressant factors (66) and pericarditis (67).
cidemia produces pulmonary vasoconstriction (68), which
an significantly contribute to right-sided HF. Acidemia
ppears to have a negative inotropic effect (69) and might,
ogether with electrolyte imbalances, contribute to an in-
(CRS) or “chronic CRS” (chronic abnormalities in cardiac function,
tration by Rob Flewell. LVH  left ventricular hypertrophy; RAA  renin angioten-drome
e illusreased risk of arrhythmias (70). Finally, renal ischemia
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Cardiorenal Syndrome November 4, 2008:1527–39tself may precipitate activation of inflammation and apo-
tosis at cardiac level (9).
A unique situation leading to type 3 CRS is bilateral
enal artery stenosis (or unilateral stenosis in a solitary
idney). Patients with this condition may be prone to
cute or decompensated HF because of diastolic dysfunc-
ion related to chronic increase of blood pressure from
xcessive activation of the renin-angiotensin-aldosterone
xis, renal dysfunction with sodium and water retention,
nd acute myocardial ischemia from an increase in
yocardial oxygen demand related to intense peripheral
asoconstriction (71,72). In these patients, angiotensin
lockade is generally required to manage the hyperten-
ion and HF. However, the GFR is highly dependent
pon angiotensin and significant decompensation of kid-
ey function may ensue. Although the management of
hese unusual patients has not been subject to scrutiny in
arge randomized trials, those exhibiting renal decom-
ensation with ACE inhibition or ARB are likely candi-
ates for renal revascularization (72).
Sensitive and specific biomarkers of cardiac injury may
elp physicians to diagnose and treat type 3 CRS earlier and
erhaps more effectively (73). Cardiac troponins are bio-
Figure 3 CRS Type 3
Pathophysiological interactions between heart and kidney in type 3 CRS or “acute
or glomerulonephritis) causing acute cardiac disorder (e.g., heart failure, arrhythm
Figure illustration by Rob Flewell.arkers for ischemic myocardial injury (74,75), and they oorrelate with outcomes in the general population and
pecifically in renal patients (76–78). A marker of myocyte
tress is BNP and allows the diagnosis of acute and acutely
ecompensated chronic HF (79). It also is an independent
redictor of cardiovascular events and overall mortality in
he general population (80,81) and also in patients with
enal insufficiency (82–84). In HF, despite high levels of
erum BNP, its physiological effects (vasodilatory, diuretic,
nd natriuretic) do not appear sufficient to prevent the
isease progression and CRS. Recent findings suggest a
esistance to BNP (85) and/or a relative preponderance of
he biologically inactive precursor of BNP (86). In CRS
ype 4 (discussed in the following text), an association
etween increased levels of BNP and the accelerated pro-
ression of nondiabetic CKD to end-stage kidney disease
as been observed (87).
Myeloperoxidase is a marker of altered myocyte metabolism,
xidative stress, and inflammation, especially in acute coronary
yndrome (88). Oxidative stress may cause myocyte apoptosis
nd necrosis, and it is associated with arrhythmias and endo-
helial dysfunction with a potential role in the pathogenesis of
RS (89). Cytokines such as tumor necrosis factor (TNF),
L-1, and IL-6 may have a diagnostic role as early biomarkers
rdiac syndrome” (abrupt worsening of renal function, e.g., acute kidney failure
onary edema). MPO  myeloperoxidase; other abbreviations as in Figure 1.renoca
ia, pulmf CRS, but also a pathogenic role causing myocardial cell
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November 4, 2008:1527–39 Cardiorenal Syndromenjury and apoptosis (90,91) and mediating myocardial damage
n ischemic AKI (92).
The development of AKI can affect the use of medica-
ions normally prescribed in patients with chronic HF. For
xample, an increase in serum creatinine from 1.5 mg/dl
130 mol/l) to 2 mg/dl (177 mol/l), with diuretic therapy
nd ACE inhibitors, may provoke some clinicians to de-
rease or even stop diuretic prescription; they may also
ecrease or even temporarily stop ACE inhibitors. This
ay, in some cases, lead to acute decompensation of HF. It
hould be remembered that ACE inhibitors do not damage
he kidney but rather modify intrarenal hemodynamics and
educe filtration fraction. They protect the kidney by reduc-
ng pathological hyperfiltration. Unless renal function fails
o stabilize, or other dangerous situations arise (i.e., hypo-
ension, hyperkalemia) continued treatment with ACE
nhibitors and ARBs may be feasible.
Finally, if AKI is severe and renal replacement therapy is
ecessary, cardiovascular instability generated by rapid fluid
nd electrolyte shifts secondary to conventional dialysis can
nduce hypotension, arrhythmias, and myocardial ischemia
93). Continuous techniques of renal replacement, which
inimize such cardiovascular instability, appear physiolog-
cally safer and more logical in this setting (94).
RS type 4 (chronic renocardiac syndrome). Type 4
RS is characterized by a condition of primary CKD (e.g.,
hronic glomerular disease) contributing to decreased car-
iac function, ventricular hypertrophy, diastolic dysfunc-
ion, and/or increased risk of adverse cardiovascular events
Fig. 4). Today, CKD is divided into 5 stages based on a
ombination of severity of kidney damage and GFR (95).
hen these criteria are used, current estimates of CKD
ccount for at least 11% of the U.S. adult population (96),
hus becoming a major public health problem. In fact CKD
oday includes individuals with serum creatinine levels
reviously dismissed as not representative of significant
enal dysfunction.
Individuals with CKD are at extremely high cardiovas-
ular risk (97). More than 50% of deaths in CKD stage 5
ohorts are attributed to cardiovascular disease. The 2-year
ortality rate after myocardial infarction in patients with
KD stage 5 is estimated to be 50% (98). In comparison,
he 10-year mortality rate post-infarct for the general
opulation is 25%. Patients with CKD have between a 10-
nd 20-fold increased risk of cardiac death compared with
ge-/gender-matched control subjects without CKD (98–
00). Part of this problem may be related to the fact that
uch individuals are also less likely to receive risk-modifying
nterventions compared to their non-CKD counterparts (101).
Less severe forms of CKD also may be associated with
ignificant cardiovascular risk. Evidence for increasing cardio-
ascular disease morbidity and mortality tracking with mild-
o-moderate renal dysfunction (stages 1 to 3) has mainly
temmed from community-based studies (102–105). These
tudies documented an inverse relationship between renal runction and adverse cardiovascular outcomes (consistently
ccurring at estimated GFR levels 60 ml/min/1.73 m2).
Among high-risk cohorts, baseline creatinine clearance is
significant and independent predictor of short-term out-
omes, namely death and myocardial infarction (99). Similar
ndings also were noted among patients presenting with
T-segment elevation myocardial infarction (106), an effect
ndependent of the Thrombolysis In Myocardial Infarction
isk score (107).
In large-scale studies (e.g., SOLVD [Studies Of Left
entricular Dysfunction], TRACE [Trandolapril Cardiac
valuation], SAVE [Survival And Ventricular Enlarge-
ent], and VALIANT [Valsartan in Acute Myocardial
nfarction]) in which the authors excluded individuals with
aseline serum creatinine of 2.5 mg/dl, reduced renal
unction was associated with significantly greater mortality
nd adverse cardiovascular event rates (108–111).
Adverse cardiovascular outcomes in renal patients are
ssociated with plasma levels of specific biomarkers
112–114). Troponins, asymmetric dimethylarginine,
lasminogen-activator inhibitor type 1, homocysteine, na-
riuretic peptides, C-reactive protein, serum amyloid A
rotein, hemoglobin, and ischemia-modified albumin are
iomarkers whose levels correlate with cardiovascular out-
omes in patients with CKD (115–117). These observations
rovide a mechanistic link between chronic inflammation
118), subclinical infections (119), accelerated atherosclero-
is, heart–kidney interactions, and negative cardiovascular
nd renal outcomes.
The proportion of individuals with CKD receiving ap-
ropriate cardiovascular risk modification treatment is lower
han in the general population. This “therapeutic nihilism”
120) is based on the concern of worsening kidney function
121,122) and leads to treating50% of patients with CKD
ith the combination of aspirin, beta-blockers, ACE inhib-
tors, and statins (123). In a cohort involving 140,000
atients, 1,025 with documented CKD were less likely to
eceive aspirin, beta-blockade, or ACE inhibition after
nfarction than patients without CKD. Yet CKD patients
ad 30-day mortality risk reductions similar to non-CKD
atients when receiving the drug combination (123).
Potential reasons for this subtherapeutic performance
nclude concerns about further worsening of renal function,
nd/or therapy-related toxic effects due to low clearance
ates (124,125). Many medications necessary for manage-
ent of complications of advanced CKD generally are
onsidered safe with concomitant cardiac disease. These
nclude regimens for calcium-phosphate balance and hyper-
arathyroidism, vitamins, and erythropoiesis-stimulating
gents (126–129). The same appears to hold true for novel
egimens, for instance, endothelin system antagonists,
denosine and vasopressin receptor antagonists, and in-
ammation suppressors (130 –133). For immunosuppres-
ive drugs, controversy exists regarding the effects of
ertain agents on the heart, indicating a need for more
esearch in the area (134).
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Cardiorenal Syndrome November 4, 2008:1527–39Bleeding concerns contribute to the decreased likelihood
f patients with severe CKD receiving aspirin and/or
lopidogrel despite the minor bleeding risk and benefits that
re sustained in these patients (135). Other medications
equiring thorough considerations of pros and cons include
iuretics, digitalis, calcium-channel blockers, and nesiritide
136–141). Nevertheless, when appropriately titrated and
Figure 4 CRS Type 4
Pathophysiological interactions between heart and kidney in type 4 cardiorenal syn
chronic glomerular disease, contributing to decreased cardiac function, cardiac hy
EPO  erythropoietin; LDL  low-density lipoprotein. Figure illustration by Rob Flewonitored, cardiovascular medications can be safely admin- mstered to CKD patients with benefits similar to the general
opulation (142).
Lack of CKD population-specific treatment effect data
akes therapeutic choices particularly challenging. In particu-
ar, in patients with advanced CKD, the initiation or increased
osage of ACE inhibitors or ARBs can precipitate clinically
ignificant worsening of renal function or marked hyperkale-
(CRS) or “chronic renocardiac syndrome” (chronic kidney disease [CKD], e.g.,
hy, or increased risk of adverse cardiovascular events). BMI  body mass index;drome
pertrop
ell.ia. The latter may be dangerously exacerbated by the use of
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November 4, 2008:1527–39 Cardiorenal Syndromeldosterone antagonists. Such patients, if aggressively treated,
ecome exposed to a significant risk of developing dialysis
ependence or life-threatening hyperkalemic arrhythmias. Yet,
f too cautiously treated, they may develop equally life-
hreatening cardiovascular complications.
It is comforting to note that up to a 30% increase in
reatinine that stabilizes within 2 months was actually
ssociated with long-term nephroprotection in a systematic
eview of 12 randomized controlled studies (143). This
esult leads to the practical advice that ACE inhibitors and
RBs can be cautiously used in patients with CKD,
rovided the serum creatinine does not increase beyond this
mount and potassium remains consistently 5.6 mmol/l.
egarding patients with end-stage renal disease, and in
articular those with anuria and a tendency to hyperkalemia
nterdialytically, the administration of ACE inhibitors or
RBs may be problematic; however, even the combination
f these medications has been used safely in select popula-
ions (144). At present, most end-stage kidney disease
atients with LV dysfunction seem to be undertreated with
CE inhibitors or ARBs (145).
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Figure 5 CRS Type 5
Pathophysiological interactions between heart and kidney in type 5 cardiorenal syn
(systemic condition, e.g., diabetes mellitus, sepsis, causing both cardiac and rena
Figure illustration by Rob Flewell.With respect to aldosterone blockade, drugs such as spi-
onolactone have been widely used for severe HF patients with
vidence of beneficial effects on morbidity and mortality (146).
oncerns have been raised, however, about the use of aldoste-
one blockade, particularly in conjunction with angiotensin
lockade, since after publication of RALES (Randomized
ldactone Evaluation Study) (146), prescriptions for spirono-
actone and rates of hospitalizations and mortality related to
yperkalemia increased sharply (147). Proper patient selection,
ncluding patients with diminished LV ejection fraction and
xcluding ones with moderate CKD (creatinine level 2.5
g/dl) or hyperkalemia 5 mmol/l, would help minimize
otential life-threatening hyperkalemia (140).
RS type 5 (secondary CRS). Type 5 CRS is character-
zed by the presence of combined cardiac and renal dysfunc-
ion due to acute or chronic systemic disorders (Fig. 5).
here is limited systematic information on type 5 CRS,
lthough there is an appreciation that as more organs fail
n this setting, mortality increases. There is limited
nsight into how combined renal and cardiovascular
ailure may differentially affect such an outcome com-
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Cardiorenal Syndrome November 4, 2008:1527–39ared to, for example, combined pulmonary and renal
ailure. Nonetheless, it is clear that several acute and
hronic diseases can affect both organs simultaneously
nd that the disease induced in one can affect the other
nd vice versa. Examples include sepsis, diabetes, amy-
oidosis, systemic lupus erythematosus, and sarcoidosis.
everal chronic conditions such as diabetes and hyper-
ension may contribute to type 2 and 4 CRS.
In the acute setting, severe sepsis represents the most
ommon and serious condition which can affect both organs. It
an induce AKI while leading to profound myocardial depres-
ion. The mechanisms responsible for such changes are poorly
nderstood but may involve the effect of TNF and other
ediators on both organs (148,149). The onset of myocardial
unctional depression and a state of inadequate cardiac output
an further decrease renal function as discussed in type 1 CRS,
nd the development of AKI can affect cardiac function as
escribed in type 3 CRS. Renal ischemia may then induce
urther myocardial injury (9) in a vicious cycle, which is
njurious to both organs. Treatment is directed at the prompt
dentification, eradication, and treatment of the source of
nfection while supporting organ function with invasively
uided fluid resuscitation in addition to inotropic and vaso-
ressor drug support.
In this setting, all the principles discussed for type 1 and 3
RS apply. In these septic patients, preliminary data derived
rom the use of more intensive renal replacement technology
uggest that blood purification may have a role in improving
yocardial performance while providing optimal small solute
learance (150). Despite the emergence of consensus defini-
ions (151) and many studies (152,153), no therapies have yet
merged to prevent or attenuate AKI in critically ill patients.
owever, evidence of the injurious effects of pentastarch fluid
esuscitation in septic AKI recently has emerged (154). Such
herapy should, therefore, be avoided in septic patients.
onclusions
n both chronic and acute situations, an appreciation of the
nteraction between heart and kidney during dysfunction of
ach or both organs has practical clinical implications. The
epth of knowledge and complexity of care necessary to offer
est therapy to these patients demands a multidisciplinary
pproach, combining the expertise of cardiology, nephrology,
nd critical care. In addition, achievement of a consensus
efinition for each type of cardiorenal syndrome will allow
hysicians to describe treatments and interventions that are
ocused and pathophysiologically sound. It will also help to
onduct and compare epidemiological studies in different
ountries and more easily identify aspects of each syndrome.
his is a priority for improvement and further research.
andomized controlled trials can then be designed to target
nterventions aimed at decreasing morbidity and mortality in
hese increasingly common conditions. Developing awareness,
he ability to identify and define, and physiological understand-
ng will help improve the outcome of these complex patients.cknowledgments
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